INTERVENTION 1:	Intervention	0
Treatment (Vorinostat, AI Therapy)	Intervention	1
vorinostat	CHEBI:45716	11-21
Patients receive vorinostat PO 5 days a week for 3 weeks. Patients also receive AI therapy comprising either anastrozole PO daily, letrozole PO daily, or exemestane PO daily for 4 weeks. Courses repeat every 28 days in the absence of disease progression and unacceptable toxicity.	Intervention	2
vorinostat	CHEBI:45716	17-27
week	UO:0000034	40-44
week	UO:0000034	51-55
week	UO:0000034	180-184
anastrozole	CHEBI:2704	109-120
letrozole	CHEBI:6413	131-140
exemestane	CHEBI:4953	154-164
disease	DOID:4,OGMS:0000031	234-241
vorinostat: Given PO	Intervention	3
vorinostat	CHEBI:45716	0-10
anastrozole: Given PO	Intervention	4
anastrozole	CHEBI:2704	0-11
letrozole: Given PO	Intervention	5
letrozole	CHEBI:6413	0-9
exemestane: Given PO	Intervention	6
exemestane	CHEBI:4953	0-10
positron emission tomography: Correlative studies	Intervention	7
positron	CHEBI:30225	0-8
tomography	BAO:0002525	18-28
F-18 16 alpha-fluoroestradiol: Correlative studies	Intervention	8
fludeoxyglucose F 18: Correlative studies	Intervention	9
f	UO:0000195	0-1
f	UO:0000195	16-17
laboratory biomarker analysis: Correlative studies	Intervention	10
biomarker	CHEBI:59163	11-20
Inclusion Criteria:	Eligibility	0
Histologically or cytologically proven diagnosis of breast cancer	Eligibility	1
breast cancer	DOID:1612	52-65
Stage IV disease	Eligibility	2
disease	DOID:4,OGMS:0000031	9-16
Patient has previously derived clinical benefit from endocrine therapy, but is no longer deriving benefit to endocrine therapy in the opinion of the treating investigator	Eligibility	3
patient	HADO:0000008,OAE:0001817	0-7
At least one site of measurable disease, as defined by the modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria	Eligibility	4
site	BFO:0000029	13-17
disease	DOID:4,OGMS:0000031	32-39
Eastern Cooperative Oncology Group (ECOG) performance status 0-2	Eligibility	5
group	CHEBI:24433	29-34
Female patient is post menopausal as defined by one of the following; free from menses for >= 2 years, surgically sterilized, FSH and estradiol in post-menopausal range AND surgical absence of uterus OR chemotherapy induced amenorrhea lasting > 1 year OR currently on ovarian suppression	Eligibility	6
female	PATO:0000383	0-6
patient	HADO:0000008,OAE:0001817	7-14
estradiol	CHEBI:23965	134-143
range	LABO:0000114	163-168
uterus	UBERON:0000995	193-199
amenorrhea	HP:0000141,DOID:13938	224-234
year	UO:0000036	96-100
year	UO:0000036	247-251
Female patient of childbearing potential has a negative urine or serum (beta human chorionic gonadotropin [B-hCG]) pregnancy test within 14 days prior to receiving the first dose of vorinostat	Eligibility	7
female	PATO:0000383	0-6
patient	HADO:0000008,OAE:0001817	7-14
urine	UBERON:0001088	56-61
chorionic gonadotropin	CHEBI:81570	83-105
vorinostat	CHEBI:45716	182-192
Male patient agrees to use two barrier methods of contraception or abstain from intercourse for the duration of the study	Eligibility	8
male	CHEBI:30780,PATO:0000384	0-4
patient	HADO:0000008,OAE:0001817	5-12
duration	PATO:0001309	100-108
Absolute neutrophil count (ANC) >= 1,500/mcL	Eligibility	9
Platelets >= 50,000/mcL	Eligibility	10
Hemoglobin >= 9 g/dL	Eligibility	11
hemoglobin	CHEBI:35143	0-10
Prothrombin time or international normalized ratio (INR) =< 1.5 x upper limit of normal (ULN) unless receiving therapeutic anticoagulation	Eligibility	12
prothrombin time	CMO:0000211	0-16
ratio	UO:0000190	45-50
x	LABO:0000148	64-65
Partial thromboplastin time (PTT) =< 1.2 times the ULN unless the patient is receiving therapeutic anticoagulation	Eligibility	13
time	PATO:0000165	23-27
time	PATO:0000165	41-45
patient	HADO:0000008,OAE:0001817	66-73
Potassium (K) levels normal limits	Eligibility	14
Magnesium (Mg) levels normal limits	Eligibility	15
Calculated creatinine clearance >= 30 mL/min	Eligibility	16
creatinine clearance	CMO:0000765	11-31
Creatinine clearance should be calculated per institutional standard	Eligibility	17
creatinine clearance	CMO:0000765	0-20
Serum total bilirubin =< 1.5 x ULN	Eligibility	18
x	LABO:0000148	29-30
Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamic pyruvate transaminase [SGPT]) =< 2.5 x ULN	Eligibility	19
aspartate	CHEBI:29995	0-9
alanine	CHEBI:16449	86-93
pyruvate	CHEBI:15361	133-141
x	LABO:0000148	50-51
x	LABO:0000148	170-171
Alkaline phosphatase =< 2.5 x ULN	Eligibility	20
phosphatase	GO:0016791,BAO:0000295	9-20
x	LABO:0000148	28-29
Patient, or the patient's legal representative, has voluntarily agreed to participate by giving written informed consent	Eligibility	21
patient	HADO:0000008,OAE:0001817	0-7
patient	HADO:0000008,OAE:0001817	16-23
Patient has a life expectancy of at least 12 weeks in the opinion of the treating investigator	Eligibility	22
patient	HADO:0000008,OAE:0001817	0-7
Patient is willing to continue on same AI therapy	Eligibility	23
patient	HADO:0000008,OAE:0001817	0-7
Patient agrees to participate in imaging protocol 7184 and is separately consented	Eligibility	24
patient	HADO:0000008,OAE:0001817	0-7
Exclusion Criteria:	Eligibility	25
Patient has not derived clinical benefit from prior endocrine therapy	Eligibility	26
patient	HADO:0000008,OAE:0001817	0-7
Patient is currently participating or has participated in a study with an investigational compound or device within 30 days of initial dosing with study drug(s) other than the imaging protocol 7184	Eligibility	27
patient	HADO:0000008,OAE:0001817	0-7
drug	CHEBI:23888	153-157
Patient has received an ER blocking therapy (selective estrogen receptor modulating or downregulating selective estrogen receptor modulator [SERM] or selective estrogen receptor degrader [SERD] i.e. tamoxifen or fulvestrant) within the past 6 weeks	Eligibility	28
patient	HADO:0000008,OAE:0001817	0-7
estrogen	CHEBI:50114,BAO:0000760	55-63
estrogen	CHEBI:50114,BAO:0000760	112-120
estrogen	CHEBI:50114,BAO:0000760	160-168
receptor	BAO:0000281	64-72
receptor	BAO:0000281	121-129
receptor	BAO:0000281	169-177
estrogen receptor modulator	CHEBI:50739	112-139
tamoxifen	CHEBI:41774	199-208
fulvestrant	CHEBI:31638	212-223
Patient had prior treatment with an histone deacetylase (HDAC) inhibitor (e.g., romidepsin [Depsipeptide], NSC-630176, MS 275, LAQ-824, belinostat (PXD-101), LBH589, MGCD0103, CRA024781, etc); patients who have received compounds with HDAC inhibitor-like activity, such as valproic acid, as anti-tumor therapy should not enroll in this study; patients who have received such compounds for other indications, e.g. valproic acid for epilepsy, may enroll after a 30-day washout period	Eligibility	29
patient	HADO:0000008,OAE:0001817	0-7
patient	HADO:0000008,OAE:0001817	193-200
patient	HADO:0000008,OAE:0001817	343-350
histone	CHEBI:15358	36-43
inhibitor	CHEBI:35222	63-72
inhibitor	CHEBI:35222	240-249
romidepsin	CHEBI:61080	80-90
depsipeptide	CHEBI:23643	92-104
belinostat	CHEBI:61076	136-146
valproic acid	CHEBI:39867	273-286
valproic acid	CHEBI:39867	413-426
epilepsy	DOID:1826	431-439
Patient is on any systemic steroids that have not been stabilized to the equivalent of =< 10 mg/day prednisone during the 30 days prior to the start of the study drugs	Eligibility	30
patient	HADO:0000008,OAE:0001817	0-7
prednisone	CHEBI:8382	100-110
Patient has known hypersensitivity to the components of study drug or its analogs	Eligibility	31
patient	HADO:0000008,OAE:0001817	0-7
hypersensitivity	GO:0002524,DOID:1205	18-34
drug	CHEBI:23888	62-66
Patients with uncontrolled brain metastases	Eligibility	32
brain	UBERON:0000955	27-32
New York Heart Association (NYHA) class III or IV congestive heart failure, myocardial infarction within the previous 6 months, QTc > 0.47 seconds, or uncontrolled arrhythmia	Eligibility	33
heart	UBERON:0000948	9-14
heart	UBERON:0000948	61-66
congestive heart failure	HP:0001635,DOID:6000	50-74
myocardial infarction	HP:0001658,DOID:5844	76-97
arrhythmia	HP:0011675	164-174
Type I diabetes mellitus; patients with type II diabetes mellitus will be included as long as their glucose can be controlled to under 200 mg/dL	Eligibility	34
type i diabetes mellitus	HP:0100651	0-24
type ii diabetes mellitus	HP:0005978	40-65
glucose	CHEBI:4167,BAO:0000924	100-107
Patient is pregnant or breast feeding, or expecting to conceive or father children within the projected duration of the study	Eligibility	35
patient	HADO:0000008,OAE:0001817	0-7
breast	UBERON:0000310	23-29
duration	PATO:0001309	104-112
Patient with a "currently active" second malignancy, other than non-melanoma skin cancer and carcinoma in situ of the cervix, should not be enrolled; patients are not considered to have a "currently active" malignancy if they have completed therapy for a prior malignancy, are disease free from prior malignancies for > 5 years or are considered by their physician to be at less than 30% risk of relapse	Eligibility	36
patient	HADO:0000008,OAE:0001817	0-7
patient	HADO:0000008,OAE:0001817	150-157
active	PATO:0002354	26-32
active	PATO:0002354	199-205
second	UO:0000010	34-40
skin cancer	DOID:4159	77-88
carcinoma	HP:0030731,DOID:305	93-102
disease	DOID:4,OGMS:0000031	277-284
Patients with known active viral hepatitis	Eligibility	37
active	PATO:0002354	20-26
viral hepatitis	HP:0006562,DOID:1884	27-42
Patient has a history or current evidence of any condition, therapy, or laboratory (lab) abnormality that might confound the results of the study, interfere with the patient's participation for the full duration of the study or is not in the best interest of the patient to participate	Eligibility	38
patient	HADO:0000008,OAE:0001817	0-7
patient	HADO:0000008,OAE:0001817	166-173
patient	HADO:0000008,OAE:0001817	263-270
history	BFO:0000182	14-21
condition	PDRO:0000129	49-58
duration	PATO:0001309	203-211
Outcome Measurement:	Results	0
Rate of Clinical Benefit of Patients Receiving Vorinostat/AI Combination Therapy According to RECIST	Results	1
rate	BAO:0080019	0-4
A 90% score (Wilson) confidence interval will be computed for the rate of clinical benefit.	Results	2
rate	BAO:0080019	66-70
Clinical benefit according to Recist score is defined as: Stable Disease, Partial Remission or Complete Remission. Lack of clinical benefit is defined as Progressive Disease (increase in target lesion size by 20% or more).	Results	3
stable	HP:0031915	58-64
disease	DOID:4,OGMS:0000031	65-72
disease	DOID:4,OGMS:0000031	166-173
progressive	HP:0003676	154-165
increase	BAO:0001251	175-183
target	BAO:0003064	187-193
size	PATO:0000117	201-205
Time frame: 8 weeks	Results	4
time	PATO:0000165	0-4
Results 1:	Results	5
Arm/Group Title: Treatment (Vorinostat, AI Therapy)	Results	6
vorinostat	CHEBI:45716	28-38
Arm/Group Description: Patients receive vorinostat PO 5 days a week for 3 weeks. Patients also receive AI therapy comprising either anastrozole PO daily, letrozole PO daily, or exemestane PO daily for 4 weeks. Courses repeat every 28 days in the absence of disease progression and unacceptable toxicity.	Results	7
vorinostat	CHEBI:45716	40-50
week	UO:0000034	63-67
week	UO:0000034	74-78
week	UO:0000034	203-207
anastrozole	CHEBI:2704	132-143
letrozole	CHEBI:6413	154-163
exemestane	CHEBI:4953	177-187
disease	DOID:4,OGMS:0000031	257-264
vorinostat: Given PO	Results	8
vorinostat	CHEBI:45716	0-10
anastrozole: Given PO	Results	9
anastrozole	CHEBI:2704	0-11
letrozole: Given PO	Results	10
letrozole	CHEBI:6413	0-9
exemestane: Given PO	Results	11
exemestane	CHEBI:4953	0-10
positron emission tomography: Correlative studies	Results	12
positron	CHEBI:30225	0-8
tomography	BAO:0002525	18-28
F-18 16 alpha-fluoroestradiol: Correlative studies	Results	13
fludeoxyglucose F 18: Correlative studies	Results	14
f	UO:0000195	0-1
f	UO:0000195	16-17
laboratory biomarker analysis: Correlative studies	Results	15
biomarker	CHEBI:59163	11-20
Overall Number of Participants Analyzed: 10	Results	16
Measure Type: Number	Results	17
Unit of Measure: percentage of patients  60        (35 to 81)	Results	18
Adverse Events 1:	Adverse Events	0
Total: 2/15 (13.33%)	Adverse Events	1
Liver failure [1]1/15 (6.67%)	Adverse Events	2
liver	UBERON:0002107	0-5
Fever [1]1/15 (6.67%)	Adverse Events	3
fever	HP:0001945	0-5
